Click here to close now.


News Feed Item

Bioniche Life Sciences Inc. Reports Q1, Fiscal 2013 Results

-quarterly revenues consistent with last year; margin on animal health product sales improves to 54%-

(all figures are in Canadian dollars unless otherwise noted)

BELLEVILLE, ON, Nov. 7, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2013 fiscal year (ended September 30, 2012).

"The Company continues to invest in several late-stage development projects and in facilities where commercial products will be made," said Mr. Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "We are nearing commercialization of some important products in the next 12 to 18 months and this requires an intensive resource allocation. Once these products reach the marketplace, we expect the new revenues will neutralize the corporate burn rate."

Further to the Company's news release of Monday, November 5, 2012, the Company continues to discuss with its licensing partner, Endo Pharmaceuticals, potential next steps for the Urocidin™ clinical program following the discontinuation of the current Phase III clinical trial in non-muscle-invasive bladder cancer. Urocidin™ remains a valuable asset and the Company is committed to ensuring that this valuable product becomes commercialized.

Fiscal 2013 First Quarter Financial Results Highlights

Revenues from the sale of Animal Health products increased by $0.5 million in the quarter, offset by a decrease in collaborative research revenue of $0.6 million. Animal Health revenues out of Canada, which includes sales into South America, declined by 17% compared to the same quarter last year due to the timing of sales orders. Sales in the United States increased 30% over the same quarter last year primarily from the introduction of new products. Sales in Australia and Europe also saw modest increases. Consolidated revenues for the quarter were $6.7 million, as compared to $6.8 million in the same period in Fiscal 2012.

The cost of sales related to product sales in the Animal Health business unit has decreased by 2% in Q1, Fiscal 2013 from the same quarter in Fiscal 2012. This decrease is directly related to increased sales from new products. Gross margins were 54.2% in Q1, Fiscal 2013, compared to 49.8% in the first quarter of last year.

The Company generated Earnings (Loss) Before Interest, Taxes, Depreciation and Amortization (EBITDA) - before research and development expenses - of ($107,000) for Q1, Fiscal 2013, as compared to ($242,000) for the same period in Fiscal 2012.

Cash, cash equivalents and short-term investments amounted to $14.4 million at September 30, 2012, as compared to $9.6 million in the same period last year and $20.0 million at June 30, 2012. A further $14 million was available to the Company at September 30, 2012 through trade and other receivables and inventories. In the same period last year, $14.6 million was available through these sources.

At September 30, 2012, the Company's net working capital totalled $21.2M as compared to working capital of $27.5M at June 30, 2012, reflecting the decrease in cash primarily used to invest in late-stage development and commercialization activities.

The Company's cash flow used in operations for the quarter ended September 30, 2012 was $5.0 million, as compared to cash used in operations of $3.9 million in the same period in Fiscal 2012. As a result, the average monthly burn rate for Q1, Fiscal 2013 was $1.8 million, vs. $1.2 million for the same quarter in Fiscal 2012.

"The Company remains committed to reducing the average monthly burn rate progressively throughout the year as it completes the development and commercialization of several new products," said Mr. Brian Ford, Chief Financial Officer of Bioniche Life Sciences Inc. "The Company's goal is to neutralize its burn rate and develop sustainable cash flows in Fiscal 2014."

The value of the Company's Property, Plant and Equipment has increased to $40.2 million at September 30, 2012, compared to $40.1 million at June 30, 2011. This increase reflects an ongoing investment in the Animal Health and Food Safety Vaccine Manufacturing Centre at the Company's corporate headquarters in Belleville, Ontario. This facility is undergoing validation to meet global GMP production standards.

Administrative expenses were $2.3 million in Q1, Fiscal 2013, as compared to $2.5 million in the same quarter last year. Marketing, selling and distribution expenses were $1.8 million in Q1, Fiscal 2013, as compared to $1.8 million in the same quarter last year. The additional expenditure in this category is related to increased staffing to support the launch and distribution of several new Animal Health products.

Research and development (R&D) expenditures for Q1, Fiscal 2013 were $4.3 million, as compared to $4.8 million in the same quarter last year. R&D resources are focused on the advancement of certain development programs in Animal Health and Food Safety. Additionally, there is continued investment in the staffing and infrastructure associated with the GMP production of the Company's UrocidinTM bladder cancer treatment. Further, until such time as the Company's Vaccine Manufacturing Centre in Belleville is making commercial product, the carrying costs associated with this facility are also accounted for under R&D.

The Company incurred financial expenses of $1.5 million (including non-cash financial expenses of $737,000) during Q1, Fiscal 2013 as a result of its US$20 million debt financing with Capital Royalty Partners. This compares to financial expenses of $0.2 million in the same quarter of Fiscal 2012.

The basic and fully-diluted net loss per share for Q1, Fiscal 2013 is ($0.06), as compared to a net loss per share of ($0.04) in the same period last year. Total Common Shares outstanding at September 30, 2012 were 103,738,712, as compared to 102,375,477 at September 30, 2011.

The Company has incurred significant losses and has an accumulated deficit of $125.5 million as at September 30, 2012, including a current loss of $6.7 million for the first quarter of Fiscal 2013. The Company's committed cash obligations and expected level of expenditures for the next twelve months exceed its committed resources of funds and funds available as at September 30, 2012.

The Company expects to finance its future expenditures by obtaining additional financing and the exploration of new partnering agreements on technologies under development. If the Company is unable to accomplish either of these initiatives, which are outside of management's control, the Company will be required to curtail its development activities and operations.

More information on the Company's year-end financial results is provided in the Company's Q1, Fiscal 2013 Management's Discussion and Analysis dated November 7, 2012.

Annual and Special Meeting of Shareholders

The Company held its Annual and Special Meeting of Shareholders in Belleville, Ontario today. At the meeting, shareholders voted in favour of electing the following individuals as members of the Board of Directors:

-Dr. Stanley Alkemade
-Mr. Albert Beraldo
-Mr. Rod Budd
-Dr. Margaret Cunningham
-Dr. James Johnson
-Mr. Graeme McRae
-Mr. Nick Photiades
-Mr. James Rae
-Mr. Lyle Vanclief

Dr. Armen Aprikian remains an Observer on the Board.

The shareholders also voted in favour of the appointment Ernst & Young, LLP, Chartered Accountants, as auditors of the Corporation.

Further, the shareholders voted in favour of an increase in the maximum number of Common Shares available to be issued under the Group Registered Retirement Savings and Employee Savings Plan ("Savings Plans") to 10,000,000.

The shareholders voted in favour of an increase in the maximum number of Common Shares available to be issued to pay outside directors to 1,400,000.

The shareholders voted in favour of a new Shareholders' Rights Plan. The Plan was originally approved in 2006 by the Toronto Stock Exchange and the shareholders. As the Plan had expired, a new Plan had to be approved.

Finally, the shareholders voted in favour of re-approval of the Amended and Restated Stock Option Plan. This Plan was approved by the shareholders in 2009 and requires re-approval by the shareholders every three years. The Stock Option Plan is a means by which the Company can compensate eligible persons for their contributions to the performance of the Company.

Other Meeting Highlights

During the meeting, additional information was presented to shareholders, including the following highlights:

  1. The Animal Health business unit has an objective of reaching $60 million in product sales revenues in Fiscal 2016.
  2. The Company's Sin Susto™ canine calming product is expected to be launched in North America in January, 2013.
  3. The Company is talking with the University of Ottawa about potential human applications for Sin Susto™.
  4. The Company's Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville, Ontario is expected to be fully validated to Good Manufacturing Practice (GMP) standards by the spring of 2013.
  5. The Company is seeking a distribution partner in Japan for Econiche®.
  6. The Company's second canine oncology product in development - Oncocidin™ - is expected to be launched in Q1, Fiscal 2014.
  7. The Company has filed new patents around Mycobacterial Cell Wall-DNA Complex (MCC) in October, 2011.
  8. A possible future indication for MCC is in human palliation following chemotherapy.
  9. The Company's R. equi vaccine for horses is undergoing proof of concept studies at the Gluck Equine Research Centre in Kentucky, where the protocol involves vaccinating mares to protect foals.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Bioniche Life Sciences Inc.
Amalgamated under the laws of Ontario

[Unaudited - see going concern uncertainty]

As at

(thousands of Canadian dollars)
30, 2012
June 30,
Cash and cash equivalents   14,409 20,020
Trade and other receivables   6,024 6,787
Inventories   7,960 7,776
Prepayments   1,065 1,081
    29,458 35,664
Property, plant and equipment   40,217 40,134
Intangible assets   5,009 5,206
Goodwill   456 456
Other non-current receivables   145 183
Deferred tax assets   375 509
Total assets   75,660 82,152
Trade and other payables   6,573 6,713
Income taxes payable   88 94
Current portion of long-term debt   1,015 997
Current portion of repayable government assistance   616 366
    8,292 8,170
Long-term debt   24,842 25,438
Repayable government assistance   31,273 30,921
Employee benefit liability   1,906 1,875
    66,313 66,404
Shareholders' equity      
Share capital   126,425 126,354
Other paid-in capital   9,429 9,327
Deficit   (125,478) (118,807)
Foreign currency translation reserve   (1,029) (1,126)
Total shareholders' equity   9,347 15,748
Total liabilities and shareholders' equity   75,660 82,152

Bioniche Life Sciences Inc. 

[Unaudited - see going concern uncertainty]

(thousands of Canadian
Series I
  Total Share
Balance, June 30, 2012 126,354     126,354   9,327   (118,807)   (1,126)   15,748
Net loss for the period         (6,671)     (6,671)
Exchange difference on translation of foreign operations           97   97
Issued under employee share ownership plan 70     70         70
Options exercised 1     1         1
Fair value of stock options vested       102       102
Balance, September 30, 2012 126,425     126,425   9,429   (125,478)   (1,029)   9,347
Balance, June 30, 2011 125,469   161   125,630   8,771   (94,619)   (1,174)   38,608
Net loss for the period         (4,509)     (4,509)
Exchange difference on translation of foreign operations           267   267
Issued under employee share ownership plan 209     209         209
Options issued to a consultant       1       1
Fair value of stock options vested       213       213
Share redemption   (161)   (161)   5       (156)
Balance, September 30, 2011 125,678     125,678   8,990   (99,128)   (907)   34,633

Bioniche Life Sciences Inc.

[unaudited - see going concern uncertainty]

For the three months ended September 30

(thousands of Canadian dollars, except share and per
share amounts)
Product   6,595 6,123
Research collaborations   74 693
    6,669 6,816
Cost of sales   3,021 3,073
Administration   2,338 2,489
Marketing and selling   1,827 1,771
Financial expenses   1,518 227
Foreign exchange loss (gain)   289 (433)
    8,993 7,127
Loss before research and development expenses and income taxes   (2,324) (311)
Research and development expenses   4,316 4,820
Less: government assistance   (98) (199)
Loss before income taxes   (6,542) (4,932)
Income tax expense (recovery)   129 (421)
Net loss for the period   (6,671) (4,511)
Exchange difference on translation of foreign operations
  97 267
Total comprehensive loss for the period   (6,574) (4,244)
Basic and diluted net loss per Share   (0.06) (0.04)
Weighted-average number of Common Shares outstanding   103,734,182 102,274,109

Bioniche Life Sciences Inc.

[unaudited - see going concern uncertainty]

For the three months ended September 30

(thousands of Canadian dollars)
Net loss for the period   (6,671) (4,511)
Items not affecting cash and other reconciling items:      
  Depreciation of property, plant and equipment   367 355
  Amortization of intangible assets   444 243
  Unrealized foreign exchange gain   (466) (99)
  Finance expense on government incentives, long-term debt
   and repayable government assistance 
  737 217
  Stock-based compensation expense   102 214
  Employee share ownership plan   208
  Employee future benefit   31 23
  Unrealized loss on other current financial assets   20
  Deemed government assistance   (7)
  Deferred income taxes   129 (361)
  Other   1
    (5,327) (3,697)
Net change in non-cash working capital balances   345 (237)
Cash used in operating activities   (4,982) (3,934)
Purchases of property, plant and equipment   (124) (2,766)
Proceeds on disposal of property, plant and equipment   2
Purchases of intangible assets   (247) (3)
Cash used in investing activities   (371) (2,767)
Proceeds from repayable government assistance   1,230
Proceeds on exercise of stock options   1
Redemption of shares   (156)
Repayment of repayable government assistance   (35)
Repayment of finance lease obligations   (108) (118)
Repayment of long-term debt   (116) (29)
Cash provided by financing activities   (258) 927
Net decrease in cash and cash equivalents during the period   (5,611) (5,774)
Cash and cash equivalents, beginning of period   20,020 15,353
Cash and cash equivalents, end of period   14,409 9,579


SOURCE Bioniche Life Sciences Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The revocation of Safe Harbor has radically affected data sovereignty strategy in the cloud. In his session at 17th Cloud Expo, Jeff Miller, Product Management at Cavirin Systems, discussed how to assess these changes across your own cloud strategy, and how you can mitigate risks previously covered under the agreement.
Countless business models have spawned from the IaaS industry – resell Web hosting, blogs, public cloud, and on and on. With the overwhelming amount of tools available to us, it's sometimes easy to overlook that many of them are just new skins of resources we've had for a long time. In his general session at 17th Cloud Expo, Harold Hannon, Sr. Software Architect at SoftLayer, an IBM Company, broke down what we have to work with, discussed the benefits and pitfalls and how we can best use them ...
Most of the IoT Gateway scenarios involve collecting data from machines/processing and pushing data upstream to cloud for further analytics. The gateway hardware varies from Raspberry Pi to Industrial PCs. The document states the process of allowing deploying polyglot data pipelining software with the clear notion of supporting immutability. In his session at @ThingsExpo, Shashank Jain, a development architect for SAP Labs, discussed the objective, which is to automate the IoT deployment proces...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, exploreed the current state of IoT connectivity and review key trends and t...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...